StockNews.com Initiates Coverage on Jaguar Health (NASDAQ:JAGX)

StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGXFree Report) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Jaguar Health Stock Performance

JAGX opened at $0.09 on Friday. The firm has a 50-day simple moving average of $0.14 and a two-hundred day simple moving average of $0.29. Jaguar Health has a 52 week low of $0.08 and a 52 week high of $4.08. The company has a debt-to-equity ratio of 22.00, a current ratio of 1.77 and a quick ratio of 1.10.

Jaguar Health (NASDAQ:JAGXGet Free Report) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.38) EPS for the quarter. The company had revenue of $2.81 million for the quarter. Jaguar Health had a negative net margin of 370.40% and a negative return on equity of 1,191.67%. Equities analysts predict that Jaguar Health will post -5.83 EPS for the current year.

Institutional Trading of Jaguar Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Jaguar Health by 141.7% during the third quarter. Vanguard Group Inc. now owns 192,335 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 112,770 shares in the last quarter. Geode Capital Management LLC bought a new stake in shares of Jaguar Health during the second quarter valued at approximately $48,000. Acadian Asset Management LLC bought a new stake in shares of Jaguar Health during the first quarter valued at approximately $43,000. Renaissance Technologies LLC raised its stake in shares of Jaguar Health by 28.6% during the fourth quarter. Renaissance Technologies LLC now owns 938,747 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 208,700 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of Jaguar Health by 152.3% during the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 321,795 shares in the last quarter. 12.24% of the stock is owned by hedge funds and other institutional investors.

About Jaguar Health

(Get Free Report)

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

See Also

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.